Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(a month ago) | |
US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(2 years from now) | |
US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(1 year, 9 months from now) | |
US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(4 years from now) | |
US9616028 | ASTRAZENECA AB | Bilayer tablet formulations |
Nov, 2030
(7 years from now) |
Qternmet Xr is owned by Astrazeneca Ab.
Qternmet Xr contains Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride.
Qternmet Xr has a total of 7 drug patents out of which 1 drug patent has expired.
Expired drug patents of Qternmet Xr are:
Qternmet Xr was authorised for market use on 02 May, 2019.
Qternmet Xr is available in tablet, extended release;oral dosage forms.
Qternmet Xr can be used as treatment of type 2 diabetes mellitus.
The generics of Qternmet Xr are possible to be released after 12 November, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | May 2, 2022 |
Market Authorisation Date: 02 May, 2019
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic